drugset / Trial / NCT02667418

Optimal Treatment for Recurrent Clostridium Difficile

NCT02667418

Phase 4 Terminated 308 enrolled VA Office of Research and Development
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether fidaxomicin and vancomycin followed by taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the treatment of recurrent Clostridium difficile infection.

Timeline

Start
2016-02-19
Primary completion
2024-08-07
Completion
2024-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fidaxomicin Other / unclassified 200 mg Oral
Subject Vancomycin Other / unclassified 125 mg Oral